We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The SEC’s two-year battle with Aveo Pharmaceuticals over the company’s embattled kidney cancer drug tivozanib has come to a close with a jury verdict against its former chief financial officer, David Johnston.